Delix Therapeutics, Inc. ("Delix")
| Private | |
| ISIN | 🆔 |
| Industry | |
| Founded 📆 | 2019 |
| Founder 👔 | |
| Headquarters 🏙️ | Boston, Massachusetts |
Area served 🗺️ | |
Key people | Mark Rus (Chief Executive Officer) |
| Members | |
Number of employees | |
| 🌐 Website | https://www.delixtherapeutics.com |
| 📇 Address | |
| 📞 telephone | |
Delix Therapeutics, Inc. is an American biotech company based in Boston, Massachusetts. The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD). It was co-founded in 2019 by David E. Olson and Nick Haft.
Company History
The company was founded to develop novel psychoplastogens.[1][2] to better treat mental health disorders[3] at scale. David E. Olson founded the company in 2019 following his discovery that psychedelics are highly potent neuroplasticity-promoting compounds.[4] In 2021, the company expanded the leadership team, adding a new CEO[5], CSO[6], and CMO[7]
Product Candidates
To date, the company has synthesized over 1000 novel psychoplastogens.[8] Many of these small molecule compounds are analogs of known psychedelics such as ibogaine and 5-MeO-DMT[9]. Delix focuses on the development of non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin[10]. Moreover, their compounds have been engineered to lack cardiotoxicity and psychostimulant properties characteristic of other first-generation psychoplastogens.[11]
Two of the company’s known compounds are tabernanthalog (TBG or DLX-7) and AAZ-A-154 (AAZ or DLX-1).[12] Delix has licensed these compounds from UC Davis.[13]
Tabernanthalog was reported to possess antidepressant and anti-addictive properties across a range of preclinical models.[14] In rodents, a single dose of Tabernanthalog reduced immobility in the forced swim test 24h after administration.[15] Additionally, a single dose reduced alcohol- and heroin-seeking behavior.[15] Tabernanthalog failed to produce a head-twitches, which are known to positively correlate with hallucinogenic potency of psychedelics in humans.[16]
Tabernanthalog was also efficacious in a mouse depression model of unpredictable mild stress (UMS).[17] The compound promoted the regrowth of dendritic spines in the prefrontal cortex that had been lost during UMS.[17] In humans, atrophy of the prefrontal cortex is associated with a broad range of stress-related diseases, including depression and PTSD.[18][19]
A single dose of AAZ-A-154 was reported to ameliorate anhedonia rapidly and sustainably in a genetic model of depression (i.e., VMAT-heterozygous mice)[20], as measured by a sucrose preference test. In wild type mice, AAZ also produces a rapid and sustained antidepressant-like effect in the forced swim test comparable to ketamine.[21] Similar to tabernanthalog, AAZ-A-154 also failed to produce head-twitches, suggesting that it is non-hallucinogenic.[21]
Key People
| Title | Name |
|---|---|
| Founder & Chief Innovation Officer | David E. Olson, PhD |
| Founder & Chairman of the Board | Nick Haft |
| Chief Executive Officer | Mark Rus, MSc |
| Chief Scientific Officer | Kurt Rasmussen, PhD |
| Chief Medical Officer | Brigitte Robertson, MD |
| Head of Corporate Strategy | Retsina Meyer, PhD |
References
- ↑ Olson, David E (January 2018). "Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics". Journal of Experimental Neuroscience. 12: 117906951880050. doi:10.1177/1179069518800508. ISSN 1179-0695. PMC 6149016. PMID 30262987.
- ↑ Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-05-18.
- ↑ "A new psychedelics player emerges to treat mental health disorders — minus the hallucinogenic effects". Endpoints News. Retrieved 2022-05-18.
- ↑ Lukasiewicz, Kacper; Baker, Jacob J.; Zuo, Yi; Lu, Ju (2021). "Serotonergic Psychedelics in Neural Plasticity". Frontiers in Molecular Neuroscience. 14: 748359. doi:10.3389/fnmol.2021.748359. ISSN 1662-5099. PMC 8545892 Check
|pmc=value (help). PMID 34712118 Check|pmid=value (help). - ↑ "Shire neuro head lands at Delix Therapeutics as CEO". FierceBiotech. 18 March 2021. Retrieved 2021-08-27.
- ↑ Lee, Yeji Jesse. "Cannabis stocks to buy now". Business Insider. Retrieved 2022-05-18.
- ↑ LaHucik, Kyle (2021-09-27). "Delix raises $70M to test psychedelic analogs for treating brain disorders in clinical trials next year". Fierce Biotech. Retrieved 2022-05-18.
- ↑ "Is the Future of Psychedelic Medicine Synthetic?". CBD Testers. 2022-05-05. Retrieved 2022-05-18.
- ↑ "Is the Future of Psychedelic Medicine Synthetic?". CBD Testers. 2022-05-05. Retrieved 2022-05-18.
- ↑ Vargas, Maxemiliano V.; Meyer, Retsina; Avanes, Arabo A.; Rus, Mark; Olson, David E. (2021). "Psychedelics and Other Psychoplastogens for Treating Mental Illness". Frontiers in Psychiatry. 12: 727117. doi:10.3389/fpsyt.2021.727117. ISSN 1664-0640. PMC 8520991 Check
|pmc=value (help). PMID 34671279 Check|pmid=value (help). - ↑ "Non-Hallucinogenic Psychedelic Analogs Could Be Game Changers for Neuropsychiatry". Neuroscience from Technology Networks. Retrieved 2022-05-18.
- ↑ Nast, Condé. "Can we take the high out of psychedelics?". Wired UK. ISSN 1357-0978. Retrieved 2022-05-18.
- ↑ Peters, Jamie; Olson, David E (January 2021). "Engineering Safer Psychedelics for Treating Addiction". Neuroscience Insights. 16: 263310552110338. doi:10.1177/26331055211033847. ISSN 2633-1055. PMC 8295933 Check
|pmc=value (help). PMID 34350400 Check|pmid=value (help). - ↑ Fell, Andy (2020-12-09). "New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression". UC Davis. Retrieved 2022-05-18.
- ↑ 15.0 15.1 "Researchers Synthesize Novel Compound, Tabernanthalog, a Non-Hallucinogenic Ibogaine Analog". Psychedelic Science Review. 2021-01-13. Retrieved 2022-05-18.
- ↑ Stephens, Tim. "Non-hallucinogenic psychedelic analog reverses effects of stress in mouse study". UC Santa Cruz News. Retrieved 2022-05-18.
- ↑ 17.0 17.1 Lu, Ju; Tjia, Michelle; Mullen, Brian; Cao, Bing; Lukasiewicz, Kacper; Shah-Morales, Sajita; Weiser, Sydney; Cameron, Lindsay P.; Olson, David E.; Chen, Lu; Zuo, Yi (2021-05-25). "An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress". Molecular Psychiatry. 26 (11): 6237–6252. doi:10.1038/s41380-021-01159-1. ISSN 1359-4184. PMC 8613316 Check
|pmc=value (help). PMID 34035476 Check|pmid=value (help). Unknown parameter|s2cid=ignored (help) - ↑ Holmes, Sophie E.; Scheinost, Dustin; Finnema, Sjoerd J.; Naganawa, Mika; Davis, Margaret T.; DellaGioia, Nicole; Nabulsi, Nabeel; Matuskey, David; Angarita, Gustavo A.; Pietrzak, Robert H.; Duman, Ronald S. (December 2019). "Lower synaptic density is associated with depression severity and network alterations". Nature Communications. 10 (1): 1529. Bibcode:2019NatCo..10.1529H. doi:10.1038/s41467-019-09562-7. ISSN 2041-1723. PMC 6449365. PMID 30948709.
- ↑ Arnsten, Amy F.T.; Raskind, Murray A.; Taylor, Fletcher B.; Connor, Daniel F. (January 2015). "The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder". Neurobiology of Stress. 1: 89–99. doi:10.1016/j.ynstr.2014.10.002. PMC 4244027. PMID 25436222.
- ↑ Fukui, M.; Rodriguiz, R. M.; Zhou, J.; Jiang, S. X.; Phillips, L. E.; Caron, M. G.; Wetsel, W. C. (2007-09-26). "Vmat2 Heterozygous Mutant Mice Display a Depressive-Like Phenotype". Journal of Neuroscience. 27 (39): 10520–10529. doi:10.1523/JNEUROSCI.4388-06.2007. ISSN 0270-6474. PMC 2855647. PMID 17898223.
- ↑ 21.0 21.1 Dong, Chunyang; Ly, Calvin; Dunlap, Lee E.; Vargas, Maxemiliano V.; Sun, Junqing; Hwang, In-Wook; Azinfar, Arya; Oh, Won Chan; Wetsel, William C.; Olson, David E.; Tian, Lin (2021-05-13). "Psychedelic-inspired drug discovery using an engineered biosensor". Cell. 184 (10): 2779–2792.e18. doi:10.1016/j.cell.2021.03.043. ISSN 0092-8674. PMC 8122087 Check
|pmc=value (help). PMID 33915107 Check|pmid=value (help).
This article "Delix Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Delix Therapeutics. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
|
This page exists already on Wikipedia. |
